The results of the study, Nadim II, from the Spanish Lung Cancer Group (GECP), have been published in the “New England Journal of Medicine” and endorse the great benefit of chemo-immunotherapy with nivolumab before operating on lung tumours in stage 3.
Nivolumab is a type of monoclonal antibody therapy, which works by stimulating the immune system to kill cancer cells.
Lung Cancer Treatment Breakthrough In Spain Could Increase Survival Rates by 20%.
Leave a reply